NOVO NORDISK A S (NONOF)

Novo Nordisk A/S (NONOF) is a large-cap biotechnology company with approximately 68,794 employees and a market capitalization of roughly $215 billion, operating across diabetes, obesity, cardiovascular, haemophilia, and rare disease franchises. The company carries an extensive late-stage pipeline dominated by Phase 3 assets across multiple diabetes formulations, with Cagrilintide (obesity) representing the most prominently flagged upcoming catalyst, estimated around May 2027. Financial details including cash position, net debt, and dilution history were not provided in the source data.